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• Celiac disease (CD) is an autoimmune disorder of the 
gastrointestinal tract that has increased in prevalence significantly 
over the recent years.  
• Occurs in genetically susceptible individuals upon ingestion of 
gluten.   
• Because gluten is the known trigger, the logical treatment option 
would be to eliminate gluten from a person’s diet, also known as, 
a gluten free diet (GFD).  
Research Questions 
Literature Review Applicability to Clinical 
Practice 
thanks . . .  
Discussion 
• Serologic testing of tissue transglutaminase antibodies has proven 
to be effective at diagnosing celiac disease when values reach a 
specific level and symptoms are supportive.   
• This conclusion is further reinforced by the modified criteria 

















• The data does however still support the need for small intestinal 
biopsy in more complex patients.   
• In addition to ESPGHAN’s modifications to the diagnostic 
criteria, additional research has concluded that a gluten free diet is 
the current effective treatment option to alleviate the effects of 
this enteropathic disease.   
• Can serologic testing alone be sufficient to confirm the diagnosis 
of celiac disease in the symptomatic patient? 
• In patients with celiac disease, what is the effect of a gluten-free 
diet in reducing symptoms compared with no treatment?   
• Gluten is a combination of proteins and found in certain grains, 
such as wheat, rye and barley.  
• It causes an immune-mediated response that can result in 
disorders such as CD.  
• CD causes mucosal damage leading to villous atrophy, crypt 
hyperplasia, and infiltration of inflammatory cells.   
• Proximal portion of the small intestine is most affected.  Impaired 











• HLA-DQ2 and HLA-DQ8 (human leukocyte antigens) - key 
players in the risk for CD in those genetically predisposed (HLA-
DQ2 present in 95% of patients diagnosed) 
• Environmental factors:  Early exposure and overexposure to 
gluten, early infection with intestinal viruses, and changes in 
bacterial flora of the gut 
• Its diagnosis is based on abnormal small intestinal histo-
pathological findings determined by endoscopic biopsy followed 
by a clinical response to a strict gluten free diet 
• Serologic testing is initial step in screening CD and the antibodies 
present include: IgA-tissue transglutaminase antibodies (IgA-
tTGA), anti-gliadin antibodies, IgA-endomysial antibodies (IgA-
EMA), deamidated gliadin antibodies.  
• The search of literature provided the following study results:  
– Mubarak et al., 2012, found that in patients with levels of IgA-
tTGA  > or equal to 100 U/mL, with improved symptoms 
following a gluten free diet, these patients had histological 
lesions compatible with CD. 
– Wakim-Fleming et al., 2013, found that symptomatic patients 
whose tTGA levels were > 118 U and who responded  to a 
GFD,  did not necessarily warrant a small intestinal biopsy.   
– Husby et al., 2012, provided the new guidelines published in 
ESPGHAN for the diagnostic criteria for CD:  If the IgA-tTG 
titers are >10 times the upper limit of normal, then the option is 
to diagnose CD without small bowel biopsies.  Strict protocol is 
to be applied including confirmation of diagnosis by an 
antibody decline and a clinical response to a gluten free diet.  
– Norstrom et al., 2012, found that all symptoms improved as 
well as significant declines in tissue transglutaminase antibody 
levels while adhering to a GFD.    
 
• Diagnosis relies heavily on practitioner suspicion.   
• Recent changes in the diagnostic criteria have created a potential 
for making a diagnosis by the healthcare provider sooner in the 
disease’s development, allowing for less damage by the disease to 
the intestinal villi.   
• Serological testing is a less invasive, less expensive approach in 
initiating a diagnosis.   
• Key elements that need to be introduced to the patient in order to 
manage their disease effectively:   
                    Consultation with a skilled dietitian 
                    Education about the disease 
                    Lifelong adherence to a GFD 
                    Identify and treat nutritional deficiencies 
                    Access to an advocacy group 
                    Continuous f/u by a multidisciplinary team 
• Health care providers are given the opportunity to screen their 
symptomatic patients with a high degree of specificity using 
serological testing.  Not all, but a vast majority of patients will be 
able to initiate treatment earlier without the need for a small 
intestinal biopsy. 
• To my supportive family.   
• To Dr. Vikki McCleary and Dr. Susan Kuntz for their guidance 
and support through this research process.   
• To the faculty and staff of the UND PA program.   
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Statement of the Problem 
• If small bowel biopsies can be disregarded as a mandatory 
diagnostic testing when specific serologic levels of 
transglutaminase antibodies are reached, then patients can avoid 
an invasive procedure and this will ultimately lead to a more rapid 







 Alicia A Hanson BS, RVT, PA-S 
 Physician Assistant Program, University of North Dakota School of Medicine & Health Sciences 
 Grand Forks, ND  58012-9037 www.med.und.nodak.edu 
Celiac Disease:  Advances in Diagnostic Testing? 
• Celiac disease (CD) is a gluten-sensitivity enteropathy that occurs 
in genetically susceptible individuals upon ingestion of gluten and 
resolves when gluten is withdrawn from one’s diet.  
• Serological markers play a major role in the diagnosis of celiac 
disease, however a small intestinal biopsy is currently the gold 
standard in symptomatic individuals.   
• The purpose of this study was to determine if serological testing 
alone is sufficient to confirm the diagnosis of CD and therefore 
eliminate the need for a biopsy.   
• The review of literature explored studies that compared small 
intestinal biopsy with different serological testing in males and 
females, <1 to 80 years in age, in order to determine if a biopsy 
was always necessary.   
http://wsm.wsu.edu/s/index.php?id=1031 
The appearance of antibodies after changing diet from gluten-free to gluten-containing. 
Decrease of antibodies level after changing diet from gluten-containing to gluten-free. 
